Back to News
Market Impact: 0.55
Raziel Therapeutics and Fosun Pharma Announce Positive Phase 3 Results for RZL-012 in Submental Fat Reduction, Clearing the Path to a China NDA Filing
Source: PR Newswire
Healthcare & BiotechRegulation & LegislationCompany Fundamentals
A 480-patient trial met all primary and secondary efficacy and safety endpoints after a single treatment cycle, with the primary responder rate showing a 30-percentage-point advantage over placebo. Fosun is planning an NDA submission to China’s regulator by year-end 2026, signaling a clear regulatory path and strengthening the program’s commercialization prospects.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.75
Ticker Sentiment
FOSUY0.85
More News
- Palantir patient data tech rejected by many NHS trusts in England
- Why did CoreWeave stock get crushed this week? Look to this corner of the debt market for clues
- Diageo's Toxic Spill Hits Pristine River in Scottish Whisky Country
- AI stock sell-off ramps up over debt-fueled data center spending fears: ‘Full-blown crisis of confidence'
- Stock fixing scandal could see Turkish companies frozen out of global indexes
- Apple’s $1,999 iPhone Duo puts the company's status-symbol power to the test